Press Releases

Osteoporosis Drugs Market at US$ 11.5 Bn in 2018 and is anticipated to contract at a CAGR of 0.3% from 2019 to 2030

According to the report, the global osteoporosis drugs market was valued at US$ 11.5 Bn in 2018 and is anticipated to contract at a CAGR of 0.3% from 2019 to 2030

The global osteoporosis drugs market for the historical period 2017–2018 and forecast period 2019–2030, rising prevalence of osteoporosis, growing aging population which is more prone to osteoporosis, and introduction of new therapies are projected to drive the global Osteoporosis Drugs market during the forecast period

High Incidence and prevalence of osteoporosis coupled with growth in geriatric population: Key Driver

Rising prevalence of osteoporosis is considered an important driver of the market, as more patients would increase demand for the drugs. Moreover, due to absence of any substantial substitute, such as surgery, demand for osteoporosis drugs is increasing constantly.

For instance, according to International Osteoporosis Foundation, Osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds and also it is estimated to affect 200 million women globally.

Furthermore, rising geriatric population is considered an important factor for growth of the market in coming years. Individuals above 50 years of age are at the greatest risk of developing osteoporosis and related fractures due to hormonal changes.

The number of people aged 65 years and above is projected to increase from 524 million in 2010 to approximately 1.5 billion in 2050. This high proportion of geriatric population is more prone to osteoporosis.

Patent expiry of blockbuster drugs and dynamic changes in pricing due to generics restrain market growth

Patent expiry and loss of exclusivity are considered major restraints of the osteoporosis drugs market. As the generic equivalents of branded drugs are manufactured and marketed at 1/10th of the price of the original branded drug, loss of patent exclusivity of a branded drug results in drastic revenue reduction amounting to almost 35% – 40% in the first year.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111904

This low cost of generics results in higher consumption, although, generic drugs are not able to achieve or exceed the overall sales of the branded formulation.

Global Osteoporosis Drugs Market: North America Dominated the global market

On the basis of region, the osteoporosis drugs market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

North America region dominated the global market owing to the presence of large number of osteoporosis patients, world-class medical infrastructure, rising awareness about the disease and its treatment and proper utilization of technologically sound devices for diagnosis purpose.

However, Asia-Pacific region is considered as the most promising market during the forecast period from 2014 to 2020. The growth is mainly attributed to factors such as steadily increasing incidence rate of osteoporosis, increasing medical expenditure, increased healthcare awareness towards diagnosis and treatment of osteoporosis and dietary habits and lack of nutritious foods.

Global Osteoporosis Drugs Market: Competitive Landscape

This report profiles major players in the global osteoporosis drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global osteoporosis drugs market is highly fragmented, with the presence of a number of international as well as regional players

Leading players operating in the global Osteoporosis Drugs market are

  • Eli Lilly and Company
  • Pfizer, Inc.
  • Amgen, Inc.
  • Merck & Co., Inc.
  • Radius Health, Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd.
  • UCB S.A.
  • Mylan N.V.
  • Apotex Inc.

Key Questions Answered in Global Osteoporosis Drugs Market Report

  • What is the scope of growth of product companies in the global osteoporosis drugs market?
  • What will be the Y-o-Y growth of the global osteoporosis drugs market between 2019 and 2027?
  • What is the influence of changing trends in pipeline products on the global osteoporosis drugs market?
  • Will North America continue to be the most profitable market for osteoporosis drugs providers?
  • Which factors are anticipated to hamper the growth of the global osteoporosis drugs market during the forecast period?
  • Which are the leading companies in the global osteoporosis drugs market?

Global Osteoporosis Drugs Market – Segmentation

Drug Class

  • Bisphosphonates
  • Calcitonin
  • RANK Ligand Inhibitor
  • Parathyroid Hormone Therapy (PTH)
  • Selective Estrogen Receptor Modulators (SERMs)
  • Sclerostin Inhibitor
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Osteoporosis Drugs Market

4. Market Overview

4.1. Introduction

4.1.1. Drug ClassDefinition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Osteoporosis Drugs Market Analysis and Forecasts, 2017–2030

4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

5.1. Pipeline Analysis

5.2. Value Chain Analysis

5.3. Key Mergers, Acquisition, and Strategic Partnerships

5.4. Osteoporosis Prevalence Globally with Key regions and Countries

6. Global Osteoporosis Drugs Market Analysis and Forecasts, By Drug Class

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast By Drug Type, 2017–2030

6.3.1. Bisphosphonates

6.3.2. Calcitonin

6.3.3. RANK Ligand Inhibitors

6.3.4. Selective Estrogen Receptor Modulators (SERMs)

6.3.5.  Parathyroid Hormone Therapy (PTH) Drugs

6.3.6.  Sclerostin Inhibitors

6.3.7. Others

6.4. Market Attractiveness By Drug Class

7. Global Osteoporosis Drugs Market Analysis and Forecasts, By Region

7.1. Key Findings

7.2. Market Value Forecast By Region

7.2.1. North America

7.2.2. Europe

7.2.3. Asia Pacific

7.2.4. Latin America

7.2.5. Middle East & Africa

7.3. Market Attractiveness By Country/Region

8. North America Osteoporosis Drugs Market Analysis and Forecast

8.1. Introduction

8.1.1. Key Findings

8.2. Market Value Forecast By Drug Type, 2017–2030

8.2.1. Bisphosphonates

8.2.2. Calcitonin

8.2.3. RANK Ligand Inhibitors

8.2.4. Selective Estrogen Receptor Modulators (SERMs)

8.2.5.  Parathyroid Hormone Therapy (PTH) Drugs

8.2.6.  Sclerostin Inhibitors

8.2.7. Others

8.3. Market Value Forecast By Country, 2017–2030

8.3.1. U.S.

8.3.2. Canada

8.4. Market Attractiveness Analysis

8.4.1. By Drug Class

8.4.2. By Country

9. Europe Osteoporosis Drugs Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. Market Value Forecast By Drug Type, 2017–2030

9.2.1. Bisphosphonates

9.2.2. Calcitonin

9.2.3. RANK Ligand Inhibitors

9.2.4. Selective Estrogen Receptor Modulators (SERMs)

9.2.5.  Parathyroid Hormone Therapy (PTH) Drugs

9.2.6.  Sclerostin Inhibitors

9.2.7. Others

9.3. Market Value Forecast By Country, 2017–2030

9.3.1. Germany

9.3.2. U.K.

9.3.2. France

9.3.2. Italy

9.3.2. Spain

9.3.2. Rest of Europe

9.4. Market Attractiveness Analysis

9.4.1. By Drug Class

9.4.2. By Country

10. Asia Pacific Osteoporosis Drugs Market Analysis and Forecast

……

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111904/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Show More

Related Articles

Back to top button